Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Assessments in ankylosing spondylitis.

Jane Zochling1, Jürgen Braun, Désirée van der Heijde

  • 1Rheumazentrum-Ruhrgebiet, Landgrafenst 15, 44649 Herne, Germany. zochling@rheumazentrum-ruhrgebiet.de

Best Practice & Research. Clinical Rheumatology
|June 17, 2006
PubMed
Summary

This review covers key measures for assessing ankylosing spondylitis (AS) disease activity, structural damage, and function. It highlights tools relevant for clinical practice and clinical trials in AS management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is active sacroiliitis on MRI associated with radiographic damage in axial spondyloarthritis? Real-life data from the ASAS and DESIR cohorts.

Rheumatology (Oxford, England)·2018
Same author

Uncovering the heterogeneity of disease impact in axial spondyloarthritis: bivariate trajectories of disease activity and quality of life.

RMD open·2018
Same author

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Lancet (London, England)·2018
Same author

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.

Lancet (London, England)·2018
Same author

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry.

Rheumatology and therapy·2018
Same author

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort.

Arthritis care & research·2018

Area of Science:

  • Rheumatology and Clinical Assessment
  • Spondyloarthritis Research

Background:

  • Ankylosing spondylitis (AS) assessment is a growing research field.
  • The Assessment in Ankylosing Spondylitis International Working Group (ASAS) has been pivotal.
  • ASAS defined core health domains, measurement instruments, and response/remission criteria for AS clinical trials and practice.

Purpose of the Study:

  • To review available measures for ankylosing spondylitis.
  • To discuss measures relevant to disease activity, structural damage, and functioning in AS.
  • To guide the selection of appropriate assessment tools for clinical practice.

Main Methods:

  • Literature review of assessment measures in ankylosing spondylitis.
  • Focus on instruments evaluating disease activity, structural damage, and functional status.

Related Experiment Videos

  • Discussion of the clinical utility of various measurement tools.

    • Main Results:

    • Several validated instruments exist for measuring AS disease activity, structural damage, and functioning.
    • The ASAS working group has established core sets and criteria for AS assessment.
    • Specific measures are recommended for different aspects of AS impact.

    Conclusions:

    • Comprehensive assessment of ankylosing spondylitis requires evaluating disease activity, structural damage, and function.
    • Validated measurement tools are available for clinical practice and research.
    • Guidelines exist to aid in selecting appropriate measures for AS patient management.